03 Mar 2014, BioSpectrum Bureau , BioSpectrum
Singapore: Fibrotech Therapeutics, based in Melbourne has secured composition of matter patents in each jurisdiction related to its proprietary antifibrotic compounds. The company has been granted patents in the US and Canada covering a prospective new class of drugs to treat fibrosis.
The new patents grant greater protection to Fibrotech's lead product, FT011 that entered phase I trials in 2013. FT011 is an antifibrotic being developed to prevent the tissue fibrosis associated with diabetic nephropathy.
"We are poised to announce phase I results for our lead product so the granting of these patents is timely and will help us greatly in ongoing partnering discussions," said Professor Darren Kelly, Fibrotech CEO.
FT011 is one of around 150 analogues of transilast in Fibrotech's portfolio. Transilast is an off-patent antifibrotic agent approved for the treatment of asthma, allergic rhinitis and atopic dermatitis in Japan.